CoChat

PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes

Guo, Yu-pei, Tang, Bei-sha, Guo, Ji-feng · 2018 · Frontiers in Neurology
Cited by 104

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fneur.2018.01100

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Research works printed but not linked: 95

  1. Gregory, 2008, Neurodegeneration associated with genetic defects in phospholipase A(2), Neurology, 71, 1402, 10.1212/01.wnl.0000327094.67726.28 · DOI · Paper page
  2. Kurian, 2008, Phenotypic spectrum of neurodegeneration associated with mutations in the PLA2G6 gene (PLAN), Neurology, 70, 1623, 10.1212/01.wnl.0000310986.48286.8e · DOI · Paper page
  3. Schneider, 2012, Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations, Mov Disord., 27, 42, 10.1002/mds.23971 · DOI · Paper page
  4. Hayflick, 2018, Neurodegeneration with brain iron accumulation, Handb Clin Neurol, 147, 293, 10.1016/B978-0-444-63233-3.00019-1 · DOI · Paper page
  5. Khateeb, 2006, PLA2G6 mutation underlies infantile neuroaxonal dystrophy, Am J Hum Genet., 79, 942, 10.1086/508572 · DOI · Paper page
  6. Paisan-Ruiz, 2010, Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations, Mov Disord., 25, 1791, 10.1002/mds.23221 · DOI · Paper page
  7. Shi, 2011, PLA2G6 gene mutation in autosomal recessive early-onset parkinsonism in a Chinese cohort, Neurology, 77, 75, 10.1212/WNL.0b013e318221acd3 · DOI
  8. Gui, 2013, Four novel rare mutations of PLA2G6 in Chinese population with Parkinson's disease, Parkins Relat Disord., 19, 21, 10.1016/j.parkreldis.2012.07.016 · DOI
  9. Gregory, 1993, PLA2G6-Associated Neurodegeneration
  10. Xie, 2015, Homozygous p.D331Y mutation in PLA2G6 in two patients with pure autosomal-recessive early-onset parkinsonism: further evidence of a fourth phenotype of PLA2G6-associated neurodegeneration, Parkinsonism Relat Disord., 21, 420, 10.1016/j.parkreldis.2015.01.012 · doi:10.1016/j.parkreldis.2015.01.012
  11. Smalheiser, 1998, Calcium-independent phospholipase A2 and schizophrenia, Arch Gen Psychiatry, 55, 752, 10.1001/archpsyc.55.8.752-a · doi:10.1001/archpsyc.55.8.752-a
  12. Ramanadham, 2003, Pancreatic islets and insulinoma cells express a novel isoform of group VIA phospholipase A2 (iPLA2 beta) that participates in glucose-stimulated insulin secretion and is not produced by alternate splicing of the iPLA2 beta transcript, Biochemistry, 42, 13929, 10.1021/bi034843p · doi:10.1021/bi034843p
  13. Morgan, 2006, PLA2G6, encoding a phospholipase A2, is mutated in neurodegenerative disorders with high brain iron, Nat Genet., 38, 752, 10.1038/ng1826 · DOI · Paper page
  14. Khan, 2014, Ophthalmic features of PLA2G6-related paediatric neurodegeneration with brain iron accumulation, Br J Ophthalmol., 98, 889, 10.1136/bjophthalmol-2013-304527 · DOI
  15. Paisan-Ruiz, 2012, Widespread Lewy body and tau accumulation in childhood and adult onset dystonia-parkinsonism cases with PLA2G6 mutations, Neurobiol Aging, 33, 814, 10.1016/j.neurobiolaging.2010.05.009 · DOI · Paper page
  16. Riku, 2013, Extensive aggregation of alpha-synuclein and tau in juvenile-onset neuroaxonal dystrophy: an autopsied individual with a novel mutation in the PLA2G6 gene-splicing site, Acta Neuropathol Commun., 1, 12, 10.1186/2051-5960-1-12 · DOI
  17. Kapoor, 2016, Genetic Analysis of PLA2G6 in 22 Indian Families with Infantile Neuroaxonal Dystrophy, Atypical Late-Onset Neuroaxonal Dystrophy and Dystonia Parkinsonism Complex, PLoS ONE, 11, e0155605, 10.1371/journal.pone.0155605 · DOI
  18. Illingworth, 2014, PLA2G6-associated neurodegeneration (PLAN): Further expansion of the clinical, radiological and mutation spectrum associated with infantile and atypical childhood-onset disease, Mol Genet Metab., 112, 183, 10.1016/j.ymgme.2014.03.008 · DOI
  19. Rohani, 2018, Oculogyric crises in PLA2G6 associated neurodegeneration, Parkins Relat Disord., 52, 111, 10.1016/j.parkreldis.2018.03.010 · doi:10.1016/j.parkreldis.2018.03.010
  20. Seitelberger, 1971, Neuropathological conditions related to neuroaxonal dystrophy, Acta Neuropathol., 17
  21. Tonelli, 2010, Novel splice-site mutations and a large intragenic deletion in PLA2G6 associated with a severe and rapidly progressive form of infantile neuroaxonal dystrophy, Clin Genet, 78, 432, 10.1111/j.1399-0004.2010.01417.x · DOI
  22. Salih, 2013, New findings in a global approach to dissect the whole phenotype of PLA2G6 gene mutations, PLoS ONE, 8, e76831, 10.1371/annotation/cb01a74a-3330-4412-8040-2a94842420ed · DOI
  23. Darling, 2018, PLA2G6-associated neurodegeneration: new insights into brain abnormalities and disease progression, Parkinsonism Relat Disord, 10.1016/j.parkreldis.2018.10.013 · DOI
  24. Gitiaux, 2018, PLA2G6-associated neurodegeneration: Lessons from neurophysiological findings, Eur J Paediatr Neurol., 22, 854, 10.1016/j.ejpn.2018.05.005 · DOI
  25. Nardocci, 1999, Infantile neuroaxonal dystrophy: clinical spectrum and diagnostic criteria, Neurology, 52, 1472, 10.1212/WNL.52.7.1472 · DOI · Paper page
  26. Crompton, 2010, Multiplex ligation-dependent probe amplification (MLPA) analysis is an effective tool for the detection of novel intragenic PLA2G6 mutations: implications for molecular diagnosis, Mol Genet Metab., 100, 207, 10.1016/j.ymgme.2010.02.009 · DOI
  27. Davids, 2016, Disruption of Golgi morphology and altered protein glycosylation in PLA2G6-associated neurodegeneration, J Med Genet., 53, 180, 10.1136/jmedgenet-2015-103338 · DOI
  28. Li, 2016, Monozygotic twins with infantile neuroaxonal dystrophy: A case report and literature review, Exp Ther Med., 12, 3387, 10.3892/etm.2016.3761 · doi:10.3892/etm.2016.3761
  29. Iannello, 2017, A new PLA2G6 mutation in a family with infantile neuroaxonal dystrophy, J Neurol Sci., 381, 209, 10.1016/j.jns.2017.08.3260 · DOI
  30. Mascalchi, 2017, Fast progression of cerebellar atrophy in pla2g6-associated infantile neuronal axonal dystrophy, Cerebellum, 16, 742, 10.1007/s12311-017-0843-z · doi:10.1007/s12311-017-0843-z
  31. Farina, 1999, Infantile neuroaxonal dystrophy: neuroradiological studies in 11 patients, Neuroradiology, 41, 376, 10.1007/s002340050768 · DOI
  32. Iodice, 2017, Infantile neuroaxonal dystrophy and PLA2G6-associated neurodegeneration: an update for the diagnosis, Brain Dev., 39, 93, 10.1016/j.braindev.2016.08.012 · DOI
  33. Wu, 2009, Clinical study and PLA2G6 mutation screening analysis in Chinese patients with infantile neuroaxonal dystrophy, Eur J Neurol., 16, 240, 10.1111/j.1468-1331.2008.02397.x · DOI
  34. Bernardi, 2011, MRI findings in patients with clinical onset consistent with Infantile Neuroaxonal Dystrophy (INAD), literature review, clinical and MRI Follow-up, Neuroradiol J., 24, 202, 10.1177/197140091102400207 · DOI
  35. Aoun, 2015, Mitochondria: A crossroads for lipid metabolism defect in neurodegeneration with brain iron accumulation diseases, Int J Biochem Cell Biol., 63, 25, 10.1016/j.biocel.2015.01.018 · DOI
  36. Sadeh, 2009, Neurodegeneration associated with genetic defects in phospholipase A2, Neurology, 73, 819, 10.1212/WNL.0b013e3181b2851b · doi:10.1212/wnl.0b013e3181b2851b
  37. Paisan-Ruiz, 2009, Characterization of PLA2G6 as a locus for dystonia-parkinsonism, Ann Neurol., 65, 19, 10.1002/ana.21415 · DOI · Paper page
  38. Karkheiran, 2015, PLA2G6-associated dystonia-parkinsonism: case report and literature review, Tremor Other Hyperkinet Mov., 5, 317, 10.7916/D84Q7T4W · DOI
  39. Virmani, 2014, Oculogyric crises induced by levodopa in PLA2G6 parkinsonism-dystonia, Parkinsonism Relat Disord., 20, 245, 10.1016/j.parkreldis.2013.10.016 · doi:10.1016/j.parkreldis.2013.10.016
  40. Kamel, 2018, PLA2G6-related parkinsonism presenting as adolescent behavior, Acta Neurol Belg., 10.1007/s13760-018-1003-z · doi:10.1007/s13760-018-1003-z
  41. Malaguti, 2015, A novel homozygous PLA2G6 mutation causes dystonia-parkinsonism, Parkinsonism Relat Disord, 21, 337, 10.1016/j.parkreldis.2015.01.001 · doi:10.1016/j.parkreldis.2015.01.001
  42. Sina, 2009, R632W mutation in PLA2G6 segregates with dystonia-parkinsonism in a consanguineous Iranian family, Eur J Neurol., 16, 101, 10.1111/j.1468-1331.2008.02356.x · DOI
  43. Giri, 2016, PLA2G6 Mutations Related to Distinct Phenotypes: A New Case with Early-onset Parkinsonism, Tremor Other Hyperkinet Mov., 6, 363, 10.7916/D81G0M12 · doi:10.7916/d81g0m12
  44. Tomiyama, 2011, PLA2G6 variant in Parkinson's disease, J Hum Genet., 56, 401, 10.1038/jhg.2011.22 · DOI
  45. Lv, 2012, Association between PLA2G6 gene polymorphisms and Parkinson's disease in the Chinese Han population, Parkinsonism Relat Disord., 18, 641, 10.1016/j.parkreldis.2012.02.015 · doi:10.1016/j.parkreldis.2012.02.015
  46. Tian, 2012, Analysis of PLA2G6 gene mutation in sporadic early-onset parkinsonism patients from Chinese population, Neurosci Lett., 514, 156, 10.1016/j.neulet.2012.02.078 · DOI
  47. Ozes, 2017, PLA2G6 mutations associated with a continuous clinical spectrum from neuroaxonal dystrophy to hereditary spastic paraplegia, Clin Genet., 92, 534, 10.1111/cge.13008 · DOI
  48. Koh, 2018, PLA2G6-associated neurodegeneration presenting as a complicated form of hereditary spastic paraplegia, J Hum Genet, 10.1038/s10038-018-0519-7. · DOI
  49. Chen, 2018, Novel PLA2G6 mutations and clinical heterogeneity in Chinese cases with phospholipase A2-associated neurodegeneration, Parkinsonism Relat Disord., 49, 88, 10.1016/j.parkreldis.2018.02.010 · doi:10.1016/j.parkreldis.2018.02.010
  50. Tan, 2010, PLA2G6 mutations and Parkinson's disease, Ann Neurol., 67, 148, 10.1002/ana.21663 · doi:10.1002/ana.21663
  51. Yoshino, 2010, Phenotypic spectrum of patients with PLA2G6 mutation and PARK14-linked parkinsonism, Neurology, 75, 1356, 10.1212/WNL.0b013e3181f73649 · DOI · Paper page
  52. Kauther, 2011, The PLA2G6 gene in early-onset Parkinson's disease, Mov Disord., 26, 2415, 10.1002/mds.23851 · DOI
  53. Agarwal, 2012, Imaging striatal dopaminergic function in phospholipase A2 group VI-related parkinsonism, Mov Disord., 27, 1698, 10.1002/mds.25160 · doi:10.1002/mds.25160
  54. Lu, 2012, PLA2G6 mutations in PARK14-linked young-onset parkinsonism and sporadic Parkinson's disease, Am J Med Genet B Neuropsychiatr Genet., 10.1002/ajmg.b.32012 · doi:10.1002/ajmg.b.32012
  55. Koroglu, 2013, Recessive truncating NALCN mutation in infantile neuroaxonal dystrophy with facial dysmorphism, J Med Genet., 50, 515, 10.1136/jmedgenet-2013-101634 · DOI · Paper page
  56. Zhang, 2013, Follow-up study of 25 Chinese children with PLA2G6-associated neurodegeneration, Eur J Neurol., 20, 322, 10.1111/j.1468-1331.2012.03856.x · doi:10.1111/j.1468-1331.2012.03856.x
  57. Goyal, 2015, Molecular diagnosis of infantile neuro axonal dystrophy by next generation sequencing, Indian J Pediatr., 82, 474, 10.1007/s12098-014-1608-z · doi:10.1007/s12098-014-1608-z
  58. Al-Maawali, 2016, Validation of the finding of hypertrophy of the clava in infantile neuroaxonal dystrophy/PLA2G6 by biometric analysis, Neuroradiology, 58, 1035, 10.1007/s00234-016-1726-6 · doi:10.1007/s00234-016-1726-6
  59. Blake, 2016, Child neurology: two sisters with dystonia and regression: PLA2G6-associated neurodegeneration, Neurology, 87, e1, 10.1212/WNL.0000000000002804 · doi:10.1212/wnl.0000000000002804
  60. Dastsooz, 2017, Novel mutations in PANK2 and PLA2G6 genes in patients with neurodegenerative disorders: two case reports, BMC Med Genet., 18, 87, 10.1186/s12881-017-0439-y · DOI
  61. Guo, 2017, Identification of novel compound mutations in pla2g6-associated neurodegeneration patient with characteristic MRI Imaging, Mol Neurobiol., 54, 4636, 10.1007/s12035-016-9991-2 · DOI
  62. Michelis, 2017, Expanded phenotype and hippocampal involvement in a novel compound heterozygosity of adult PLA2G6 associated neurodegeneration (PARK14), Parkinsonism Relat Disord., 37, 111, 10.1016/j.parkreldis.2017.01.005 · doi:10.1016/j.parkreldis.2017.01.005
  63. Wirth, 2017, Severe early-onset impulsive compulsive behavior and psychosis in PLA2G6-related juvenile Parkinson's disease, Parkinsonism Relat Disord., 41, 127, 10.1016/j.parkreldis.2017.05.014 · doi:10.1016/j.parkreldis.2017.05.014
  64. Yamashita, 2017, Mutation screening of PLA2G6 in Japanese patients with early onset dystonia-parkinsonism, J Neural Transm., 124, 431, 10.1007/s00702-016-1658-7 · DOI
  65. Elsayed, 2018, Case report of a novel homozygous splice site mutation in PLA2G6 gene causing infantile neuroaxonal dystrophy in a Sudanese family, BMC Med Genet., 19, 72, 10.1186/s12881-018-0592-y · DOI
  66. Ferese, 2018, Heterozygous PLA2G6 mutation leads to iron accumulation within basal ganglia and Parkinson's disease, Front Neurol., 9, 536, 10.3389/fneur.2018.00536 · DOI
  67. Shen, 2018, Genetic analysis of ATP13A2, PLA2G6 and FBXO7 in a cohort of Chinese patients with early-onset Parkinson's disease, Sci Rep., 8, 14028, 10.1038/s41598-018-32217-4 · DOI
  68. Wang, 2018, Infantile neuroaxonal dystrophy caused by PLA2G6 gene mutation in a Chinese patient: a case report, Exp Ther Med., 16, 1290, 10.3892/etm.2018.6347 · DOI
  69. Malley, 2018, The structure of iPLA2beta reveals dimeric active sites and suggests mechanisms of regulation and localization, Nat Commun., 9, 765, 10.1038/s41467-018-03193-0 · DOI · Paper page
  70. Ma, 1999, Human pancreatic islets express mRNA species encoding two distinct catalytically active isoforms of group VI phospholipase A2 (iPLA2) that arise from an exon-skipping mechanism of alternative splicing of the transcript from the iPLA2 gene on chromosome 22q13.1, J Biol Chem., 274, 9607, 10.1074/jbc.274.14.9607 · DOI
  71. Hooks, 2008, Role of Ca2+-independent phospholipase A2 in cell growth and signaling, Biochem Pharmacol., 76, 1059, 10.1016/j.bcp.2008.07.044 · DOI
  72. Ackermann, 1994, Ca(2+)-independent cytosolic phospholipase A2 from macrophage-like P388D1 cells. Isolation and characterization, J Biol Chem., 269, 9227, 10.1016/S0021-9258(17)37098-9 · DOI · Paper page
  73. Tang, 1997, A novel cytosolic calcium-independent phospholipase A2 contains eight ankyrin motifs, J Biol Chem., 272, 8567, 10.1074/jbc.272.13.8567 · DOI · Paper page
  74. Balsinde, 2005, Cellular regulation and proposed biological functions of group VIA calcium-independent phospholipase A2 in activated cells, Cell Signal., 17, 1052, 10.1016/j.cellsig.2005.03.002 · DOI · Paper page
  75. Farooqui, 2004, Brain phospholipases A2: a perspective on the history, Prostaglandins Leukot Essent Fatty Acids, 71, 161, 10.1016/j.plefa.2004.03.004 · DOI
  76. Shirai, 2004, Specific differential expression of phospholipase A2 subtypes in rat cerebellum, J Neurocytol., 33, 297, 10.1023/B:NEUR.0000044191.83858.f7 · doi:10.1023/b:neur.0000044191.83858.f7
  77. Farooqui, 2006, Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders, Pharmacol Rev., 58, 591, 10.1124/pr.58.3.7 · DOI · Paper page
  78. Calandria, 2010, Neuroprotectin D1 modulates the induction of pro-inflammatory signaling and promotes retinal pigment epithelial cell survival during oxidative stress, Adv Exp Med Biol., 664, 663, 10.1007/978-1-4419-1399-9_76 · DOI
  79. Sun, 2018, Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases, Prostaglandins Leukot Essent Fatty Acids, 136, 3, 10.1016/j.plefa.2017.03.006 · DOI · Paper page
  80. Cámara-Lemarroy, 2010, Molecular inflammatory mediators in peripheral nerve degeneration and regeneration, Neuroimmunomodulation, 17, 314, 10.1159/000292020 · DOI · Paper page
  81. Broersen, 2018, Structural and aggregation properties of alpha-synuclein linked to phospholipase A2 Action, Protein Pept Lett., 25, 368, 10.2174/0929866525666180326120052 · doi:10.2174/0929866525666180326120052
  82. Malik, 2008, Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations, Am J Pathol., 172, 406, 10.2353/ajpath.2008.070823 · DOI · Paper page
  83. Adibhatla, 2010, Lipid oxidation and peroxidation in CNS health and disease: from molecular mechanisms to therapeutic opportunities, Antioxid Redox Signal., 12, 125, 10.1089/ars.2009.2668 · DOI · Paper page
  84. Kinghorn, 2015, Loss of PLA2G6 leads to elevated mitochondrial lipid peroxidation and mitochondrial dysfunction, Brain, 138, 1801, 10.1093/brain/awv132 · DOI · Paper page
  85. Lin, 2018, Phospholipase PLA2G6, a Parkinsonism-Associated Gene, Affects Vps26 and Vps35, Retromer Function, and Ceramide Levels, Similar to alpha-Synuclein Gain, Cell Metab., 28, 605, 10.1016/j.cmet.2018.05.019 · DOI · Paper page
  86. Iliadi, 2018, Mutations in the Drosophila homolog of human PLA2G6 give rise to age-dependent loss of psychomotor activity and neurodegeneration, Sci Rep., 8, 2939, 10.1038/s41598-018-21343-8 · DOI · Paper page
  87. Sanchez, 2018, Pla2g6 deficiency in zebrafish leads to dopaminergic cell death, axonal degeneration, increased beta-synuclein expression, and defects in brain functions and pathways, Mol Neurobiol., 55, 6734, 10.1007/s12035-017-0846-2 · DOI
  88. Chiu, 2018, PARK14 (D331Y) PLA2G6 causes early-onset degeneration of substantia nigra dopaminergic neurons by inducing mitochondrial dysfunction, ER stress, mitophagy impairment and transcriptional dysregulation in a knockin mouse model, Mol Neurobiol., 10.1007/s12035-018-1118-5. · DOI
  89. Strokin, 2017, Neurons and astrocytes in an infantile neuroaxonal dystrophy (INAD) mouse model show characteristic alterations in glutamate-induced Ca(2+) signaling, Neurochem Int., 108, 121, 10.1016/j.neuint.2017.03.004 · DOI
  90. Sun, 2004, Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases, J Lipid Res., 45, 205, 10.1194/jlr.R300016-JLR200 · DOI · Paper page
  91. Lopez-Vales, 2011, Phospholipase A2 superfamily members play divergent roles after spinal cord injury, FASEB J., 25, 4240, 10.1096/fj.11-183186 · DOI
  92. Palavicini, 2017, Oligomeric amyloid-beta induces MAPK-mediated activation of brain cytosolic and calcium-independent phospholipase A2 in a spatial-specific manner, Acta Neuropathol Commun., 5, 56, 10.1186/s40478-017-0460-6 · DOI
  93. Engel, 2010, Catalytic function of PLA2G6 is impaired by mutations associated with infantile neuroaxonal dystrophy but not dystonia-parkinsonism, PLoS ONE, 5, e12897, 10.1371/journal.pone.0012897 · DOI · Paper page
  94. Klein, 2016, PLA2G6mutations and Parkinsonism: long-term follow-up of clinical features and neuropathology, Mov Disord., 31, 1927, 10.1002/mds.26814 · doi:10.1002/mds.26814
  95. Rogers, 2013, DHA supplementation: current implications in pregnancy and childhood, Pharmacol Res., 70, 13, 10.1016/j.phrs.2012.12.003 · DOI · Paper page

Cited by

See all 104

Metadata

Authors
Guo, Y.-P., Tang, B.-S., & Guo, J.-F.
Venue
Frontiers in Neurology
Published
2018-12-18
Volume
9
ISSN
1664-2295
Cited by
104
References
1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes. https://app.cochat.ai/papers/10.3389/fneur.2018.01100
The paper
Guo, Y.-P., Tang, B.-S., & Guo, J.-F. (2018). PLA2G6-Associated Neurodegeneration (PLAN): Review of Clinical Phenotypes and Genotypes. Frontiers in Neurology. https://doi.org/10.3389/fneur.2018.01100

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.